FDA
-
-
-
-
-
-
-
Axovant (AXGT) Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
-
-
-
-
-
-
-
Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs
-
-
-
-
-
-
-
Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

